VC  The Column Group

http://www.thecolumngroup.net





     Office Locations:

1700 Owens Street, Suite 500
San Francisco, CA 94158
Phone: 415-865-2050
Fax: 415-255-2048

 

Stages:

  • Early
  • Expansion
  • Growth
  • Seed


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    The Column Group is a venture capital firm dedicated to creating the next generation of biotechnology companies. The firm will invest in approximately 10-12 disease-focused drug discovery companies (per fund), each with the potential to become a leader in their respective field(s). Typically, Column will commit $15M to $30M per company, fostering their growth from seed and early stage to later stages of development. The Column Group will primarily focus on early stage drug discovery companies, an area currently underserved by many biotech venture capital funds. The firm is currently evaluating opportunities in the areas of cancer, inflammation, infectious disease, metabolic disorders, cardiovascular disease and nervous system disorders.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or Silicon Valley Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    David V. Goeddel Ph.D. Managing Partner
    Helen S. Kim Partner
    Larry Lasky Partner
    Peter Svennilson Managing Partner
    Robert Tjian Discovery Partner

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      05/18/2018


      Accent Therapeutics


      MA


      $40,000,000


      Series A


      05/09/2018


      Escient Pharmaceuticals


      CA


      $40,000,000


      Series A


      04/09/2018


      Constellation Pharmaceuticals


      MA


      $100,000,000


      


      02/22/2018


      Kallyope


      NY


      $66,000,000


      Series B


      12/21/2017


      FLX Bio


      CA


      $60,000,000


      Series C


      11/09/2017


      Exonics Therapeutics


      MA


      $40,000,000


      Series A


      09/07/2017


      Gritstone Oncology


      CA


      $92,700,000


      Series B


      07/24/2017


      Effector Therapeutics


      CA


      $38,600,000


      Series C


     

    Portfolio companies include:


      3-V bioscienes
        web link


      Accent Therapeutics
        web link


      Aragon Pharmaceuticals
        web link


      Arcus Biosciences
        web link


      Constellation Pharmaceuticals
        web link


      Cyterix Pharmaceuticals
        web link


      Effector Therapeutics
        web link


      Escient Pharmaceuticals
        web link


      Exonics Therapeutics
        web link


      FLX Bio
        web link


      Gritstone Oncology
        web link


      Igenica
        web link


      Immune Design
        web link


      Kallyope
        web link


      NGM Biopharmaceuticals
        web link


      Nurix
        web link


      ORIC Pharmaceuticals
        web link


      Peloton Therapeutics
        web link


      PTC Therapeutics
        web link


      REVOLUTION Medicines
        web link


     

    Recent News:


      There is no recent news for The Column Group.